On 26 July 2023, Parkway Life REIT (“PLife”) announced their half year result for the financial year 2023. Overall I would say their fundamentals remain relatively unchanged and is a stable REIT for investment. Whether it justifies their high P/B ratio is another question but up to each investors own risk appetite.
The overall cost of debt of PLife also remained unchanged this quarter. They may continue to be well managed and not be heavily affected as the interest rates are expected to increase for the rest of the year. Excluding any unforseen circumstances, their DPU growth likely to continue uptrend and uninterrupted, providing investors assurance on stability.
Website: Financial Statements And Related Announcement::Half Yearly Results
Photo source: https://fifthperson.com/2021-parkway-life-reit-agm/
Background
PLife is one of Asia’s largest listed healthcare Real Estate Investment Trusts (“REIT”). It invests in income-producing real estate and real estate-related assets used primarily for healthcare and healthcare-related purposes.
It owns the largest portfolio of strategically located private hospitals in Singapore comprising Mount Elizabeth Hospital, Gleneagles Hospital and Parkway East Hospital. In addition, it has assets located in Japan, including one pharmaceutical product distributing and manufacturing facility in Chiba Prefecture as well as 56 high quality nursing home and care facility properties in various prefectures of Japan. It also owns strata-titled units/lots at Kuala Lumpur in Malaysia.
PLife have been expanding their Japan nursing homes over the last few years. Japan is one of the countries with the highest aging population and if they can leverage their expertise, they can move to other countries once aging population becomes a problem there. Due to lower birth rates and, ironically, advancements in healthcare, aging population is an increasing situation in almost every country around the world.
Key Metrics
Distribution Per Unit (“DPU”)
| Metrics | Current | Previous |
|---|---|---|
| Distribution Per Unit | +3.3% | +2.5% |
DPU have increased by 3.3% to SGD0.0729 for the first half of 2023 as compared to the same period in the previous financial year. The increase in DPU is mainly attributable to the increase in gross revenue.
This metric is Favorable as the DPU growth is organic.
Occupancy
| Metrics | Current | Previous |
|---|---|---|
| Occupancy | 99.7% | 99.7% |
Occupancy rate as at 30 June 2023 stands at 99.7%, unchanged from the previous quarter. It is worth noting that their Singapore and Japan assets are committed at 100%, which are the major components of their assets. It is pulled down by PLife’s sole Malaysian medical center, which stood at 31%. It is above my expected healthy occupancy rate of 95% and PLife have been able to fully utilize their assets.
This metric is Favorable.
Gearing ratio
| Metrics | Current | Previous |
|---|---|---|
| Gearing Ratio | 35.3% | 37.5% |
Gearing ratio stands at 35.3% as at 30 June 2023, decreased from 37.5% in the previous quarter. The decrease in this quarter was largely due to the depreciation of Japanese Yen and repayment of fixed rate note, partially offset by drawdown of short term loans for Capex and working capital purposes.
This metric to me is Favorable as it is still a distance from the MAS limits.
Interest coverage
| Metrics | Current | Previous |
|---|---|---|
| Interest Coverage | 13.8x | 15.6x |
The interest coverage stands at 13.8 times, attributable by their low cost of debt of 1.19%. This is Favorable.
The Federal Reserve on 26 July 2023 has once again hiked the interest rates by a quarter percentage point to a range between 5.00% and 5.25%, the highest level in 22 years and are likely to keep it at these levels over the next few years.
Website: Fed approves hike that takes interest rates to highest level in more than 22 years
Despite the increase over the last few months, the overall cost of debt of PLife did not increase substantially, allowing them to continue enjoying high interest coverage and be in a comfortable position.
Nonetheless, as the interest rate may potentially increase further, PLife may be subjected to significant change in their cost of debt in the near future. In their presentation they have mentioned that 77% of their interest rate have been hedged. Furthermore a portion of their debt is also on fixed rates.
I have thus performed a sensitivity analysis using the information as at 30 June 2023:
| Description | Amount (SGD’000) |
|---|---|
| Total Debt | $807,400 |
| Debt Not Hedged (%) | 23% |
| Debt at Floating Rate Exposed | $185,702 |
| Distributable Income FY2022 | $87,004 |
Interest rate sensitivity analysis as below:
| Change in Interest Rates | Decrease in Distributable Income (SGD’000) | Change as % of FY2022 Distribution |
|---|---|---|
| + 50 bps | -$929 | -1.0% |
| + 100 bps | -$1,857 | -2.0% |
| + 150 bps | -$2,786 | -3.0% |
| + 200 bps | -$3,714 | -4.0% |
| + 250 bps | -$4,643 | -5.0% |
| + 300 bps | -$5,571 | -6.0% |
Do note the above is my estimation which may be different from management’s estimation. Nonetheless, if the interest rates were to increase by the basis points above, PLife may experience a fall in DPU accordingly.
Debt maturity profile
| Metrics | Current | Previous |
|---|---|---|
| Debt Maturity Profile | 2.9 years | 3.1 years |
Weighted average term to maturity of their debt stands at 2.9 years as at 30 June 2023. This is Favorable and it allows them sufficient time to refinance their debts as they fall due.
Price to Book Ratio
| Metrics | Current | Previous |
|---|---|---|
| Price to Book Ratio | 1.64 | 1.69 |
The Price to Book (“P/B”) ratio currently stands at 1.64. This is computed using the closing share price of SGD3.82 on 4 August 2023 and the net asset value per share of SGD2.33 as at 30 June 2023. The P/B ratio is Unfavorable.
It was worth noting however that the share price continued to rise despite being grossly overvalued. We will cover more in the “Key Things to Note” section.
Dividend yield
| Year | Yield | Total |
|---|---|---|
| 2023 | 3.82% | SGD 0.146 |
| 2022 | 2.78% | SGD 0.106 |
| 2021 | 3.69% | SGD 0.141 |
| 2020 | 3.55% | SGD 0.136 |
| 2019 | 3.44% | SGD 0.131 |
| 2018 | 3.40% | SGD 0.130 |
The distribution for the calendar year 2022 is lower than 2023 due to in 2022 PLife have switched to semi-annual distribution.
With the total dividend payout of SGD0.146 per share for the full calendar year 2023 and closing share price of SGD3.82 on 4 August 2023, this translates to a dividend yield of 3.82%. For my benchmark, a general reasonable range would be around an average of 5.5% to 6.5% given the current environment. A yield of 3.82% sounds similar to growth equity stocks from other industries.
Website: Reasonable Dividend Yield 2023Q3
Nonetheless, there are some interesting rationale for the dividend yield to be compressed and will be covered more in the “Key Things to Note” section.
The dividend yield is Neutral.
Possible Expansion Targets
Third Pillar
There are currently 2 pillars supporting PLife REIT. They are:
- The Hospitals in Singapore
- The Nursing Homes in Japan
Since the previous years, PLife have mentioned they will be looking to venture into a new market and develop a new stream of revenue. Based on the announcement of 26 July 2023, management is still keen to build a 3rd Key Market which can contribute enhanced growth for PLife in the mid to long term.
While the timing of this is uncertain, in my opinion it is certainly welcoming. This will allow for them to diversify their revenue and not rely on a single tenant for a large proportion of their revenue.
Based on their financial results, they are in a good position to do so. Despite the recent fall in share price, PLife is still trading at a high P/B ratio. With the high P/B ratio as well as the heavily compressed yield, it would not be difficult for them to find a yield accretive target. It was worth noting as well that it will work in management’s favor to issue rights to capitalize on the high P/B ratio. Till date, management have not done so and the recent acquisitions were funded by debt. We will see as time progresses.
Key Things to Note
Expensive getting more expensive
There is no denying that PLife is a relatively more expensive REIT compared to others that are available in the market. A yield of 3.82% and P/B ratio of 1.64 exposes investors to higher risks. Given the straightforward business of REITs, their fair value usually should trade around their net asset value.
The key thing to note however, unlike most other REITs, PLife have income visibility. Especially with the renewal of 20 years lease, which contributes a substantial portion of their income and servers as a bulwark for PLife as they explore new initiatives. Not to mention that this lease agreement also takes into consideration the Consumer Price Index (“CPI”), and is designed to increase overall rent payable based on the CPI. This is an effective hedge against inflation, which has been breaking historic highs recently.
Based on its dividend records, we can also see that they have steadily increase dividend payout over the years. Its stability and transparency is the reason for its high premium.
Nonetheless, it is still expensive, and something that investors should take note off and decide if they are comfortable with it before investing. If the market decides to crash, PLife’s can easily lose 50% of its market value as it is trading at a price that is close to double its book value.
Tenant concentration
Parkway Hospitals Singapore Pte. Ltd. is their top tenant contributing 63.3% of gross revenue. This indicates a heavy concentration of revenue and puts the REIT at the mercy of their customer.
While they have renewed the lease for 20 years, they are still dependent on the financial position of their customers. Cashflows have been tightening for all businesses and rental expense is one of the significant overheads that tenants will wish to cut down on. This might adversely affect the DPU of the REIT moving forward.
It is worth nothing however that the top tenant is a wholly owned subsidiary of Parkway Pantai Limited, who is a wholly owned subsidiary of Kuala Lumpur-based IHH Healthcare, Asia’s largest private healthcare group. IHH Healthcare is also in a good financial position, based on their latest financial highlights.
Website: IHH Healthcare Financial Highlights
The largest shareholders of IHH Healthcare are Mitsui of Japan (one of the largest sogo shosha in Japan) and then followed by the Malaysian government’s sovereign wealth fund Khazanah Nasional.
This leads me to not expect the tenants to run into cash flow problems in the short term.
Summary
| Metrics | Financials | Rating |
|---|---|---|
| Distribution Per Unit | +3.3% | Favorable |
| Occupancy | 99.7% | Favorable |
| Gearing Ratio | 35.3% | Favorable |
| Interest Coverage | 13.8x | Favorable |
| Debt Maturity Profile | 2.9 years | Favorable |
| Price to Book Ratio | 1.64 | Unfavorable |
| Overall | Favorable |
Overall, the metrics indicate that it is favorable to invest in PLife. Their fundamentals have remained relatively unchanged this quarter and therefore this suggests that the current share price is due to overall market sentiment. With the interest rates continue to be expected to increase over the next few months, safe assets may see their yield rise considerably with rising interest rates. There may be opportunities for adding if the share price see a fall.
They are also recession proof as healthcare continues to be in demand and aging population becomes a widespread problem. A third pillar could potentially see PLife become even more attractive if it enters into a new market that is easily defensible.
Disclaimer: Not financial advice. All data and information provided on this site is for informational purposes only.
Previous Post
Website: Parkway Life REIT (SGX: C2PU): 2023 First Quarter Business Update
